During the past decade, Stanford Cancer Institute Palo Alto conducted 208 clinical trials. In the 10-year time frame, 208 clinical trials started and 150 clinical trials were completed, i.e. on average, 72.1% percent of trials that started reached the finish line to date. In the past 5 years, 73 clinical trials started and 69 clinical trials were completed. i.e. 94.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Stanford Cancer Institute Palo Alto" #1 sponsor was "National Cancer Institute (NCI)" with 104 trials, followed by "SWOG Cancer Research Network" with 27 trials sponsored, "Stanford University" with 25 trials sponsored, "Children's Oncology Group" with 21 trials sponsored and "Gilead Sciences" with 21 trials sponsored. Other sponsors include 256 different institutions and companies that sponsored additional 122 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Stanford Cancer Institute Palo Alto" #1 collaborator was "National Cancer Institute (NCI)" with 150 trials as a collaborator, "NRG Oncology" with 29 trials as a collaborator, "Cancer and Leukemia Group B" with 11 trials as a collaborator, "Canadian Cancer Trials Group" with 9 trials as a collaborator and "SWOG Cancer Research Network" with 9 trials as a collaborator. Other collaborators include 98 different institutions and companies that were collaborators in the rest 65 trials.

According to Clinical.Site data, the most researched conditions in "Stanford Cancer Institute Palo Alto" are "Lymphoma" (23 trials), "Leukemia" (19 trials), "Breast Cancer" (18 trials), "Chronic Lymphocytic Leukemia" (12 trials) and "Lung Cancer" (11 trials). Many other conditions were trialed in "Stanford Cancer Institute Palo Alto" in a lesser frequency.

Most popular intervention types in "Stanford Cancer Institute Palo Alto" are "Drug" (358 trials), "Biological" (144 trials), "Other" (137 trials), "Procedure" (84 trials) and "Radiation" (75 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (76 trials), "Quality-of-Life Assessment" (48 trials), "Paclitaxel" (34 trials), "Cisplatin" (32 trials) and "Computed Tomography" (30 trials). Other intervention names were less common.

The vast majority of trials in "Stanford Cancer Institute Palo Alto" are 393 trials for "All" genders, 45 trials for "Female" genders and 16 trials for "Male" genders.

Currently, there are 210 active trials in "Stanford Cancer Institute Palo Alto". 3 are not yet recruiting, 87 are recruiting, 116 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 188 completed trials in Stanford Cancer Institute Palo Alto, 10 suspended trials, and 35 terminated clinical trials to date.

Out of the total trials that were conducted in Stanford Cancer Institute Palo Alto, 96 "Phase 1" clinical trials were conducted, 201 "Phase 2" clinical trials and 171 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 28 trials that are defined as “Not Applicable".